Biofrontera AG Return on Equity

Biofrontera AG (BFRA) currently reports a ROE of 2526.34%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore Biofrontera AG's ROE history and peer comparisons.

Biofrontera AG's ROE of 2526.34% is higher than the Healthcare sector average of 13.1%. That is roughly 19179.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biofrontera AG's current 2526.34% should be judged against Healthcare norms (sector average: 13.1%) and against BFRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 2526.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Biofrontera AG, and consider following BFRA for alerts when major investors trade the stock.

Biofrontera AG is classified in the Healthcare sector. On ROE, it currently shows 2526.34% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BFRA with unrelated industries.